Published in Genetics and Environmental Business Week, January 3rd, 2008
Key to the success of the Company's artificial liver device are HepaLife's patented PICM-19 embryonic liver stem cells, which scientists have demonstrated possess a number of unique characteristics, making their liver-specific metabolic functionality superior to other cells, including the world's most widely used human liver cell line.
The unique functionality of the PICM-19 cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.